Effect of atorvastatin on lipoprotein (a) and interleukin-10: A randomized placebo-controlled trial;Effet de l'atorvastatine sur la lipoprotéine (a) et l'interleukine-10 essai contrôlé et randomisé en double-insu contre placebo

Diabetes and Metabolism

Volumn 37, Issue 2, 2011, Pages 124-130

  Hernandez C ^a,b   Francisco, G ^a,b   Ciudin, A ^b   Chacon P ^b   Montoro, B ^b   Llaverias, G ^a,c   Blanco Vaca, F ^a,c,d   Simo R ^a,b,d  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Atorvastatin; Hypercholesterolaemia; Interleukin 10; Lipoprotein (a); Randomized study; TNF receptor; Vascular inflammation

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; INTERLEUKIN 10; INTERLEUKIN 6; LIPOPROTEIN; PLACEBO; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL;

AGED; ANTICHOLESTEREMIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; INTERLEUKIN-10; LIPOPROTEIN(A); MALE; MIDDLE AGED; PLACEBOS; PYRROLES;

EID: 79955066200     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabet.2010.08.006     Document Type: Article

References (33)

1. Braunwald E. Shattuck lecture-cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med 1997, 337:1360-1369.
2. Sacks F.M., Pfeffer M.A., Moye L., Brown L.E., Hamm P., Cole T.G., et al. Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Events trial (CARE). Am J Cardiol 1991, 68:1436-1446.
3. Danesh J., Collins R., Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000, 102:1082-1085.
4. Luc G., Bard J.M., Arveiler D., Ferrieres J., Evans A., Amouyel P., et al. Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study. Atherosclerosis 2002, 163:377-384.
5. Ariyo A.A., Thach C., Tracy R., Cardiovascular Health Study Investigators Lp(a) lipoprotein, vascular disease, and mortality in the elderly. N Engl J Med 2003, 349:2108-2115.
6. Hernández C., Francisco G., Chacón P., Simó R. Lipoprotein(a) as a risk factor for cardiovascular mortality in type 2 diabetic patients: a 10-year follow-up study. Diabetes Care 2005, 28:931-933.
7. Hernández C., Chacón P., García-Pascual L., Simó R. Differential influence of LDL-Cholesterol and triglycerides on lipoprotein(a) concentration in diabetic patients. Diabetes Care 2001, 24:350-355.
8. Noma A., Abe A., Maeda S., Seishima M., Makino K., Yano Y., et al. Lp(a): an acute-phase reactant?. Chem Phys Lipids 1994, 67-8:411-417.
9. Wade D.P., Clarke J.G., Lindahl G.E., Liu A.C., Zysow B.R., Meer K., et al. 5' Control regions of the apolipoprotein(a) gene and members of the related plasminogen gene family. Proc Natl Acad Sci U S A 1993, 90:1369-1373.
10. Francisco G., Hernández C., Simó R. Serum markers of vascular inflammation in dyslipemia. Clin Chim Acta 2006, 369:1-16.
11. Danesh J., Wheeler J.G., Hirscheld G.M., Eda S., Eiriksdottir G., Rumley A., et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004, 350:1387-1397.
12. Bennet A., Di Angelantonio E., Erqou S., Eiriksdottir G., Sigurdsson G., Woodward M., et al. Lipoprotein (a) levels and risk of future coronary heart disease: large-scale prospective data. Arch Intern Med 2008, 168:598-608.
13. Fieseler H.G., Armstrong V.W., Wieland E., Thiery J., Schütz E., Walli A.K., et al. Serum Lp(a) concentrations are unaffected by treatment with the HMG-CoA reductase inhibitor Pravastatin: results of a 2-year investigation. Clin Chim Acta 1991, 204:291-300.
14. Klausen I.C., Gerdes L.U., Meinertz H., Hansen F.A., Faergeman O. Apolipoprotein(a) polymorphism predicts the increase of Lp(a) by pravastatin in patients with familial hypercholesterolaemia treated with bile acid sequestration. Eur J Clin Invest 1993, 23:240-245.
15. Sampietro T., Galetta F., Bionda A. Behavior of Lp(a) and apoproteins (A1, B, C2, C3, E) during and after therapy with simvastatin. Cardiovasc Drugs Ther 1995, 9:785-789.
16. van Wissen S., Smilde T.J., Trip M.D., de Boo T., Kastelein J.J., Stalenhoef A.F. Long term statin treatement reduces lipoprotein (a) concentrations in heterozygous familial hypercholesterolemia. Heart 2003, 9:893-896.
17. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection. Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421.
18. Lipid research clinics program. Manual of laboratory operations, lipid and lipoprotein analysis 1982, US Government Printing Office, National Heart, Lung and Blood Institute, [(HEW publ. no. NIH 75-628, revised), Bethesda MD]. 2nd edition. A. Hainline, J. Karon, K. Lippel (Eds.).
19. Gonbert S., Malinsky S., Sposito A.C., Milionis H.J., Mikhailidis D.P., Elisaf M.S., et al. Atorvastatin lowers lipoprotein(a) but not apolipoprotein(a) fragment levels in hypercholesterolemic subjects at high cardiovascular risk. Atherosclerosis 2002, 164:305-311.
20. Goudevenos J.A., Bairaktari E.T., Chatzidimou K.G., Milionis H.J., Mikhailidis D.P., Elisaf M.S. The effect of atorvastatin on serum lipids, lipoprotein(a) and plasma fibrinogen levels in primary dyslipidaemia-a pilot study involving serial sampling. Curr Med Res Opin 2001, 16:269-275.
21. Ozaki K., Kubo T., Imaki R., Shinagawa H., Fukaya H., Ohtaki K., et al. The anti-atherosclerotic effects of lipid lowering with atorvastatin in patients with hypercholesterolemia. J Atheroscler Thromb 2006, 13:216-219.
22. Tsimikas S., Witztum J.L., Miller E.R., Sasiela W.J., Szarek M., Olsson A.G., et al. Myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) Study Investigators. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation 2004, 110:1406-1412.
23. Hernández C., Francisco G., Chacón P., Mesa J., Simó R. Biological variation of lipoprotein(a) in a diabetic population. Analysis of the causes and clinical implications. Clin Chem Lab Med 2003, 41:1075-1080.
24. Krempler F., Kostner G.M., Roscher A., Sandholfer F. Studies on the role of specific cell surface receptor on the removal of Lp(a) in man. J Clin Invest 1983, 71:1431-1441.
25. Rader D.J., Man W.A., Cain W., Kraft H.G., Usher D., Zech L.A., et al. The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans. J Clin Invest 1995, 95:1403-1408.
26. Kostner G.M., Gavish D., Leopold B., Bolzano K., Weintraub M.S., Breslow J.L. HMG CoA-reductase inhibitors lower LDL-cholesterol levels without reducing Lp(a) levels. Circulation 1988, 80:1313-1319.
27. Wang J., Hu B., Kong L., Cai H., Zhang C. Native, oxidized lipoprotein(a) and lipoprotein(a) immune complex in patients with active and inactive rheumatoid arthritis: plasma concentrations and relationship to inflammation. Clin Chim Acta 2008, 390:67-71.
28. Krysiak R., Gdula-Dymek A., Bachowski R., Okopien B. Pleiotropic effects of atorvastatin and fenofibrate in metabolic syndrome and different types of prediabetes. Diabetes Care 2010, 33:2266-2270.
29. Ridker P.M., Danielson E., Fonseca F.A., Genest J., Gotto A.M., Kastelein J.J., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195-2207.
30. Stumpf C., Petzi S., Seybold K., Wasmeier G., Arnold M., Raaz D., et al. Atorvastatin enhances interleukin-10 levels and improves cardiac function in rats after acute myocardial infarction. Clin Sci 2008, 116:45-52.
31. Dushkin M.I., Khoshchenko O.M., Kudinova E.N., Schwartz Ysh. Effects of hydroxysterols and atorvastatin on lipopolysaccharide-induced secretion of tumor necrosis factor and interleukin-10 by mouse macrophages. Bull Exp Biol Med 2006, 141:233-235.
32. Paul F., Waiczies S., Wuerfel J., Bellmann-Strobl J., Dorr J., Waiczies H., et al. Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis. PLoS ONE 2008, 3:e1928.
33. Horiuchi Y., Hirayama S., Soda S., Seino U., Kon M., Ueno T., et al. Statin therapy reduces inflammatory markers in hypercholesterolemic patients with high baseline levels. J Atheroscler Thromb 2010, 17:722-729.